Dembighshire, United Kingdom

Christopher John Smith


Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 35(Granted Patents)


Location History:

  • Dembighshire, GB (2001)
  • Clwyd, GB (2001)

Company Filing History:


Years Active: 2001

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Christopher John Smith: Innovator in Antigenic Protein Research

Introduction

Christopher John Smith is a notable inventor based in Denbighshire, GB. He has made significant contributions to the field of immunology, particularly through his innovative work on antigenic proteins. With a total of 5 patents to his name, Smith has established himself as a key figure in the development of vaccines and diagnostic methods.

Latest Patents

Smith's latest patents include groundbreaking work on the nucleic acid encoding OMP26 antigen from Haemophilus influenzae. This novel antigenic protein is derived from the outer membrane and has potential applications in vaccines. His inventions also encompass methods for immunizing subjects against infections, as well as techniques for the prophylaxis or treatment of respiratory tract infections and otitis media. Additionally, he has developed diagnostic methods utilizing the OMP26 antigen, which includes kits for detection and treatment.

Career Highlights

Throughout his career, Smith has been associated with Provalis UK Limited, where he has furthered his research and development efforts. His work has not only advanced scientific understanding but has also contributed to public health initiatives.

Collaborations

Smith has collaborated with notable colleagues such as Jennelle Kyd and Allan William Cripps. These partnerships have enhanced the scope and impact of his research, leading to innovative solutions in the field of immunology.

Conclusion

Christopher John Smith's contributions to the field of antigenic protein research are significant and impactful. His innovative patents and collaborations continue to advance the understanding and treatment of infectious diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…